## What is claimed is:

30

Crystalline sodium (2S,3S)-3-[[(1S)-1-iso-butoxymethyl-3-methylbutyl]carbamoyl]oxirane-2-carboxylate having the following characteristics:

DSC: exothermic peak observed at a temperature in the range of 170 to 175°C with weight decrease; and characteristic absorption bands of infrared absorption spectrum measured on KBr tablet: 3255, 2950, 2860, 1670, 1630, 1550, 1460, 1435, 1395, 1365, 1310, 1260, 1110, 890 cm<sup>-1</sup>.

Crystalline potassium (2S,3S)-3-[[(1S)-1-iso-butoxymethyl-3-methylbutyl]carbamoyl]oxirane-2-carboxylate having the following characteristics:

DSC: exothermic peak observed at 177°C with weight decrease; and

characteristic absorption bands of infrared absorp20 tion spectrum measured on KBr tablet: 3270, 3080, 2950,
2870, 1680, 1625, 1560, 1460, 1380, 1300, 1240, 1110, 895
cm<sup>-1</sup>.

- 3. A process for preparation of crystalline sodium 25 or potassium (2S,3S)-3-[[(1S)-1-isobutoxymethyl-3-methyl-butyl]carbamoyl]oxirane-2-carboxylate, comprising the following steps (1) to (6):
  - (1) hydrolyzing an ester of (2S,3S)-3-[[(1S)-1-isobutoxymethyl-3-methylbutyl]carbamoyl]oxirane-2-carbox-ylic acid, to obtain (2S,3S)-3-[[(1S)-1-isobutoxymethyl-3-methylbutyl]carbamoyl]oxirane-2-carboxylic acid,
  - (2) causing the carboxylic acid obtained in the preceding step react with an organic amine, to prepare a salt of (2S,3S)-3-[[(1S)-1-isobutoxymethyl-3-methyl-butyllgarbarevllevirges 2 carboxylic acid with the organ
- butyl]carbamoyl]oxirane-2-carboxylic acid with the organic amine,

- (3) adding an acid to the salt obtained in the preceding step, to obtain (2S,3S)-3-[[(1S)-1-isobutoxy-methyl-3-methylbutyl]carbamoyl]oxirane-2-carboxylic acid,
- (4) causing the carboxylic acid obtained in the preceding step react with a basic sodium or potassium compound in a mixed solvent of water and an aliphatic alcohol or acetone, to obtain a sodium or potassium salt,

5

10-

20

25

- (5) recrystallizing the sodium or potassium salt obtained in the preceding step using an aliphatic alcohol, and
- (6) drying the product recrystallized in the preceding step under reduced pressure.
- 4. A process for preparation of crystalline sodium 15 or potassium (2S,3S)-3-[[(1S)-1-isobutoxymethyl-3-methyl-butyl]carbamoyl]oxirane-2-carboxylate, comprising the following steps (1) to (4):
  - (1) causing an ester of (2S,3S)-3-[[(1S)-1-iso-butoxymethyl-3-methylbutyl]carbamoyl]oxirane-2-carboxylic acid react with a basic sodium or potassium compound, to obtain sodium or potassium (2S,3S)-3-[[(1S)-1-isobutoxymethyl-3-methylbutyl]carbamoyl]oxirane-2-carboxylate,
  - (2) crystallizing the sodium or potassium salt obtained in the preceding step from a mixed solvent of water and acetone, to obtain crystalline sodium or potassium salt.
  - (3) recrystallizing the sodium or potassium salt obtained in the preceding step using an aliphatic alcohol, and
- 30 (4) drying the product recrystallized in the preceding step under reduced pressure.
- 5. A salt of (2S,3S)-3-[[(1S)-1-isobutoxymethyl-3-methylbütyl]carbamoyl]oxirane-2-carboxylic acid with an organic amine.

6. A salt of (2S,3S)-3-[[(1S)-1-isobutoxymethyl-3methylbutyl]carbamoyl]oxirane-2-carboxylic acid with an organic amine represented by the formula of:

 $(R^1)$   $(R^2)$   $(R^3)$  N

5

in which R<sup>1</sup> is hydrogen or a linear-chain, branched-chain or cyclic alkyl group having 1 to 10 carbon atoms; R2 is hydrogen or a linear-chain, branched-chain or cyclic -alkyl-or-aralkyl-group of 1 to 10 carbon atoms; and R3 is a linear-chain, branched-chain or cyclic alkyl group having 1 to 10 carbon atoms which may have a substituent selected from the group consisting of halogen atoms, nitro, hydroxyl, carboxyl, quanidino, amino and aralkylamino groups; or otherwise R2 and R3 can be combined to 15 form a 5- to 7-membered ring comprising the nitrogen atom to which R<sup>2</sup> and R<sup>3</sup> are connected, the ring possibly containing additional nitrogen atom.

20 7. A salt of (2S,3S)-3-[[(1S)-1-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3-isobutoxymethyl-3methylbutyl]carbamoyl]oxirane-2-carboxylic acid with an organic amine selected from the group consisting of piperazine, adamantane amines, cyclohexylamine, dicyclohexylamine, tris(hydroxymethyl)aminomethane, arginine, 25 lysine, benzathine, and meglumine.